Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium lactate is an alkalinizing agent that is metabolized to bicarbonate in the liver, increasing plasma bicarbonate concentration and buffering hydrogen ions, thereby correcting metabolic acidosis. The lactate ion is converted to pyruvate and then to glucose or oxidized via the Krebs cycle, yielding bicarbonate.
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
Treatment of mild to moderate metabolic acidosis,Correction of acid-base imbalance in conditions such as diabetic ketoacidosis (as an adjunct),Fluid resuscitation in hypovolemic states when alkalinization is desired (off-label)
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
Intravenous infusion; initial dose 300-500 m L (50-83 mmol) administered over 1-2 hours; subsequent doses based on serum bicarbonate and clinical response. Maximum infusion rate: 300 m L/h.
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
Lactate has a plasma half-life of approximately 5-10 minutes in healthy individuals. In patients with hepatic impairment or shock, half-life may be prolonged to 1-2 hours due to reduced metabolism.
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Lactate is metabolized primarily in the liver via lactate dehydrogenase to pyruvate, then enters the gluconeogenesis pathway or the Krebs cycle for oxidation to carbon dioxide and water, generating bicarbonate. Metabolism is dependent on hepatic function.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Sodium lactate is metabolized to bicarbonate primarily in the liver (60-70%) and kidneys (30-40%). Excretion of unmetabolized lactate is minimal (<5%) via urine. Biliary/fecal excretion negligible.
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
Lactate is not significantly protein-bound (<1%). It is freely filtered and metabolized.
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
Volume of distribution for lactate is approximately 0.3-0.5 L/kg, reflecting distribution into total body water and rapid cellular uptake.
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Only relevant route is intravenous; oral lactate is rapidly metabolized in the liver (first-pass effect), but no IV bioavailability data exists; effectively 100% for IV administration.
Intravenous: 100%.
GFR 30-50 m L/min: caution, monitor for volume overload and electrolyte disturbances; GFR <30 m L/min: avoid due to risk of sodium overload and metabolic alkalosis. No specific dose reduction; use with close monitoring.
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
Child-Pugh A-B: no adjustment; Child-Pugh C: caution due to impaired lactate metabolism; monitor for acidosis/alkalosis.
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
Neonates and infants: 2-5 m L/kg (0.33-0.83 mmol/kg) intravenously over 1-2 hours; repeated as needed based on acid-base status. Children: 5-10 m L/kg (0.83-1.66 mmol/kg) IV over 1-2 hours. Maximum infusion rate: 5 m L/kg/h.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Start at lower end of adult dose (300 m L) due to decreased renal function and risk of fluid overload; monitor electrolytes and volume status closely.
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
None
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
Use with caution in patients with impaired liver function, as conversion to bicarbonate may be reduced,Risk of metabolic alkalosis with excessive administration,Should not be used in severe metabolic acidosis (p H < 7.1) or lactic acidosis,Monitor serum electrolytes, p H, and fluid status during administration,Contains sodium; use with caution in patients with congestive heart failure, edema, or renal impairment
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
Severe metabolic acidosis (p H < 7.1),Lactic acidosis,Alkalosis,Hypernatremia,Fluid overload states,Severe hepatic failure (inability to convert lactate to bicarbonate),Known hypersensitivity to sodium lactate or any component of the formulation
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
No significant food-drug interactions are known. However, patients on sodium-restricted diets should be informed of the sodium content of this solution.
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
Sodium lactate, as a component of lactated Ringer's solution, is generally considered safe during pregnancy. No teratogenic effects have been reported in humans. It is used intravenously for fluid and electrolyte replacement. The risk to the fetus is minimal when used according to standard clinical practice across all trimesters.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
Sodium lactate is a normal component of breast milk and is not expected to cause adverse effects. The M/P ratio is not specifically defined but is likely similar to plasma levels. Use during breastfeeding is considered safe.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
Standard dosing for fluid and electrolyte replacement is generally appropriate during pregnancy. No specific dose adjustments are typically required, but careful monitoring of volume status and electrolytes is recommended due to potential pregnancy-related changes in renal function and hemodynamics.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
Sodium lactate 0.167 Molar is an isotonic crystalloid solution primarily used as a source of bicarbonate precursors in metabolic acidosis. Monitor serum lactate levels to distinguish iatrogenic hyperlactatemia from lactic acidosis. Avoid in patients with severe metabolic alkalosis or hypernatremia. Use with caution in hepatic impairment due to impaired lactate clearance. In cardiac arrest, consider use only if indicated by arterial blood gas; routine use is not recommended.
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
This intravenous solution provides electrolytes and fluid to help correct body acid imbalance.,Tell your healthcare provider if you have a history of liver disease, kidney problems, or are on a low-sodium diet.,Report any symptoms such as muscle twitching, confusion, or irregular heartbeat during infusion.,You may experience temporary discomfort or swelling at the infusion site.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER is a Electrolyte Solution that works by Sodium lactate is an alkalinizing agent that is metabolized to bicarbonate in the liver, increasing plasma bicarbonate concentration and buffering hydrogen ions, thereby correcting metabolic acidosis. The lactate ion is converted to pyruvate and then to glucose or oxidized via the Krebs cycle, yielding bicarbonate.. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER is: Intravenous infusion; initial dose 300-500 m L (50-83 mmol) administered over 1-2 hours; subsequent doses based on serum bicarbonate and clinical response. Maximum infusion rate: 300 m L/h.. The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER is classified as Category C. Sodium lactate, as a component of lactated Ringer's solution, is generally considered safe during pregnancy. No teratogenic effects have been reported in humans. It is used intrave. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.